CN115554421B - Skin tissue light transparent reagent and preparation method and application thereof - Google Patents
Skin tissue light transparent reagent and preparation method and application thereof Download PDFInfo
- Publication number
- CN115554421B CN115554421B CN202210444740.9A CN202210444740A CN115554421B CN 115554421 B CN115554421 B CN 115554421B CN 202210444740 A CN202210444740 A CN 202210444740A CN 115554421 B CN115554421 B CN 115554421B
- Authority
- CN
- China
- Prior art keywords
- imaging
- skin tissue
- light transparent
- optical imaging
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims abstract description 90
- 238000003384 imaging method Methods 0.000 claims abstract description 61
- 238000012634 optical imaging Methods 0.000 claims abstract description 38
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000001054 cortical effect Effects 0.000 claims abstract description 16
- 229930006000 Sucrose Natural products 0.000 claims description 39
- 239000005720 sucrose Substances 0.000 claims description 39
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 22
- 210000004761 scalp Anatomy 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 210000003710 cerebral cortex Anatomy 0.000 claims description 5
- 230000001066 destructive effect Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 25
- 239000003961 penetration enhancing agent Substances 0.000 abstract description 25
- 150000001720 carbohydrates Chemical class 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 17
- 238000005516 engineering process Methods 0.000 abstract description 10
- 210000000601 blood cell Anatomy 0.000 abstract description 7
- 238000003333 near-infrared imaging Methods 0.000 abstract description 6
- 238000000482 two photon fluorescence microscopy Methods 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 81
- 238000012014 optical coherence tomography Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000005715 Fructose Substances 0.000 description 8
- 229930091371 Fructose Natural products 0.000 description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000003128 head Anatomy 0.000 description 7
- 210000003625 skull Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 238000002834 transmittance Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000005885 Buprofezin Substances 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- PRLVTUNWOQKEAI-VKAVYKQESA-N buprofezin Chemical compound O=C1N(C(C)C)\C(=N\C(C)(C)C)SCN1C1=CC=CC=C1 PRLVTUNWOQKEAI-VKAVYKQESA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to a skin tissue light transparent reagent, which comprises the following components in parts by mass: 100 parts of heavy water, 160-210 parts of saccharides and 19-32 parts of alcohol polymer penetration enhancer. The skin tissue light transparent reagent is prepared from a formula comprising heavy water, saccharides and alcohol polymer permeation promoters according to a specific proportion, and is applied to the preparation of an optical imaging auxiliary preparation, the obtained optical imaging auxiliary preparation has better transparency to skin, can realize high-resolution imaging of cortical blood vessels and cells under the condition of keeping the integrity of the skin, is non-invasive, can be combined with various optical imaging technologies such as OCT imaging, two-photon fluorescence imaging, near infrared imaging, photoacoustic imaging and the like, has high transparency speed and good imaging effect, is a nondestructive optical imaging method, and has simple operation method and wider application range.
Description
Technical Field
The invention relates to the technical field of biomedical optical imaging, in particular to a skin tissue light transparent reagent and a preparation method and application thereof.
Background
High-resolution and visual research of the brain is a key for exploring the occurrence and development processes of craniocerebral diseases, and along with the rapid development of optical imaging technology and fluorescent marking methods, living monitoring of dynamic change processes of cerebral blood vessels and cells becomes possible. The dynamic changes of the cortical blood vessels are monitored by a living body imaging technology, for example, parameters such as blood flow, blood oxygen metabolism level and the like are dynamically monitored, so that the method is helpful for revealing the time-space change characteristics of the cerebral blood vessels and cells under the physiological and pathological conditions, and has important significance for research, diagnosis and symptomatic treatment guidance of cerebral vascular diseases.
However, the high scattering properties of the skin and skull tissue surrounding the brain severely limit the effectiveness of optical imaging techniques to perform transcranial living cortex imaging, and the clouding properties of the skin and skull tissue limit the penetration depth of light in the tissue, so that conventional optical imaging techniques can only image shallow layers and have low image contrast and resolution. In order to overcome the limitation in the current research, the scalp of the living animal is usually cut off, then skull removal or thinning operation is carried out, and then cortex imaging is carried out to obtain an imaging result with higher resolution. However, this method has a number of drawbacks, such as: on one hand, the scalp of a living animal is cut and sutured to be invasive, the complexity of the operation is increased, and on the other hand, the skull removal and thinning can induce the cortex bleeding and inflammatory response, not only can interfere the imaging effect, but also can cause the aggravation of the illness state.
In the current development of research, it has been pointed out that cortical vascular imaging based on intact skin and skull tissue can be performed by injecting near infrared fluorescent dyes. However, the current research results greatly depend on the development and optimization of novel fluorescent probes, and are only applicable to near infrared fluorescent imaging technology, so that the application range is limited. The development of tissue light transparent technology provides a new idea for applying skin tissue light transparent reagent on the skin of the head of a living animal, so that the skin tissue is transparent, and cerebral cortex blood vessels are further revealed, so as to implement non-invasive cortical blood vessel or cell imaging. However, the currently reported skin tissue light transparent reagent has limited transparent effect or application range, and the skin tissue light transparent reagent which can be widely popularized and applied is not developed on the market.
Disclosure of Invention
Based on this, it is necessary to provide a skin tissue photopermeability agent which can make the skin of the head of a living animal transparent, and which can realize high resolution imaging of cortical blood vessels and cells in combination with an optical imaging technique. The method is non-invasive and has a wide range of applications.
Further, it is necessary to provide a preparation method and application of the skin tissue light transparent reagent.
The invention provides a skin tissue light transparent reagent, which comprises the following components in parts by mass:
100 parts of heavy water,
160-210 parts of saccharides
19-32 parts of alcohol polymer penetration enhancer.
In one embodiment, the composition comprises the following components in parts by mass:
100 parts of heavy water,
185-205 parts of saccharides
22-25 parts of alcohol polymer penetration enhancer.
In one embodiment, the saccharide is at least one of sucrose and fructose; and/or
The alcohol polymer penetration enhancer is at least one of PEG-400 and PEG-200.
In one embodiment, the saccharide is sucrose and the alcohol polymer permeation enhancer is PEG-400.
The invention also provides a preparation method of the skin tissue light transparent reagent in any embodiment, which comprises the following steps:
mixing the heavy water, the saccharide and the alcohol polymer penetration enhancer.
In one embodiment, the method comprises the following steps:
dissolving the saccharide in the heavy water to prepare a saccharide-containing solution;
the sugar-containing solution is mixed with the alcohol polymer permeation enhancer.
In one embodiment, the mass to volume ratio of the saccharide to the heavy water is 2.03g to 1ml; and/or the volume ratio of the sugar-containing solution to the alcohol polymer permeation enhancer is 4:1.
The invention also provides the use of a skin tissue light transparent agent as described in any of the embodiments above as a preparation for an optical imaging aid.
In one embodiment, the optical imaging aid is used to perform non-destructive optical imaging of the cortex.
In one embodiment, the optical imaging in a lossless manner comprises the steps of:
the optical imaging assistant preparation is smeared on the surface of the scalp to make the scalp transparent and expose the cortical blood vessels, and then imaging is carried out.
The skin tissue light transparent reagent is composed of a formula comprising heavy water, saccharides and alcohol polymer penetration enhancers, is prepared by a specific proportion, is applied to the preparation of an optical imaging auxiliary preparation, has better transparency to skin, can realize high-resolution imaging of cortical blood vessels and cells under the condition of keeping the integrity of the skin, is noninvasive, and can be combined with various optical imaging technologies such as OCT imaging, two-photon fluorescence imaging, near infrared imaging, photoacoustic imaging and the like, and the application range is wider.
Drawings
Fig. 1 is a graph showing the comparison of the transmittance of heavy water and conventional water molecules in the near infrared region.
FIG. 2 shows the results of the transparency property test of the skin tissue light transparent agent of example 1 and comparative examples 1 to 2.
FIG. 3 is the results of the transparency capability performance test of the skin tissue light transparent agent of example 1 and comparative example 3.
Fig. 4 is an imaging result of the skin tissue light transparent agent of example 2 in combination with the OCT apparatus.
Fig. 5 is an imaging result of the skin tissue light transparent agent of example 3 in combination with a two-photon imaging system.
Detailed Description
In order to facilitate the understanding of the present invention, the skin tissue light transparent agent of the present invention, and the preparation method and application thereof will be more fully described with reference to the accompanying drawings and examples. This invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
In the present invention, "further", "still further", "particularly" and the like are used for descriptive purposes to indicate differences in content but should not be construed as limiting the scope of the invention.
In the invention, the technical characteristics described in an open mode comprise a closed technical scheme composed of the listed characteristics and also comprise an open technical scheme comprising the listed characteristics.
The embodiment of the invention provides a skin tissue light transparent reagent, which comprises the following components in parts by mass:
100 parts of heavy water,
160-210 parts of saccharides
19-32 parts of alcohol polymer penetration enhancer.
The traditional skin tissue light transparent reagent adopts water as a solvent, however, the inventor finds that the water has strong absorption to most of near infrared light (800 nm-1050 nm and 1150 nm-1700 nm), wherein 800 nm-1050 nm and 1300nm are common excitation light wavelengths for two-photon imaging and OCT imaging, and the water is used as the solvent to cause strong attenuation of signals, which is unfavorable for imaging. In the spectrum absorption, the characteristic absorption peak of the heavy water is relatively red-shifted and the absorption intensity is weakened because of one more neutron of the deuterium element, and the heavy water is selected as a solvent, so that the heavy water has higher transmittance in the wavelength range, has small influence on signals and is more beneficial to imaging. As shown in FIG. 1, the transmittance of heavy water and conventional water molecules in the near infrared light (800 nm-1050 nm, 1150 nm-1700 nm) is significantly different, and the transmittance of heavy water in the near infrared light (800 nm-1050 nm, 1150 nm-1700 nm) is significantly higher than that of conventional water molecules in the wavelength range.
Furthermore, the chemical property of the heavy water is almost the same as that of the conventional water molecules, and the saccharides and the alcohol polymer penetration enhancer have good solubility in the heavy water, so that the heavy water is selected as the solvent in the skin tissue light transparent reagent, so that the good signal intensity in imaging analysis can be ensured, the solvent has good solubility to other components in the reagent, and the skin tissue transparentizing effect of the reagent is ensured.
It will be appreciated that permeation enhancers are a class of agents that are effective in promoting permeation of agents into the skin, thereby further enhancing the transparentization of skin tissue. In one specific example provided by this embodiment, the permeation enhancer is an alcohol polymer permeation enhancer. In the traditional technology, the penetration enhancer with the capability of enhancing the transparent effect also comprises dimethyl sulfoxide and thioketone, but the dimethyl sulfoxide has stronger irritation to skin and is not beneficial to being used in-vivo research. The buprofezin has poor solubility in heavy solvent water, and the buprofezin is used as a permeation promoter, so that the skin tissue light transparent reagent can only be prepared for use and can not be stored for a long time, and the reagent becomes turbid after being stood for too long time, and has more use restrictions. Therefore, in one embodiment of the invention, the alcohol polymer is preferably used as the penetration enhancer, the action effect of the alcohol polymer penetration enhancer is mild, no obvious stimulation effect is generated on skin and mucous membrane, the solubility in the solvent is good, the stability is strong, and the prepared skin tissue photopermeability agent has longer storage life.
Further, the skin tissue light transparent reagent comprises the following components in parts by mass:
100 parts of heavy water,
185-205 parts of saccharides
22-25 parts of alcohol polymer penetration enhancer.
In a specific example, the saccharide may be, for example, but not limited to, at least one of a monosaccharide and a disaccharide. Further, fructose is preferable as the monosaccharide, sucrose is preferable as the disaccharide, and both fructose and sucrose can achieve a certain degree of transparency of the skin tissue. Still further, the saccharide is preferably sucrose, and the sugar-containing solution formed after the sucrose is dissolved in heavy water can further improve the transparency degree of skin tissue.
In a specific example, the alcohol polymer permeation enhancer may be, for example, but not limited to, a polymer of the polyethylene glycol (PEG) series. Further, the polymerization degree of PEG is preferably 200 to 600. It is understood that the degree of polymerization of PEG may be, for example, but not limited to, 200, 300, 400, 500, 600. Further, the alcohol polymer permeation enhancer is preferably at least one of PEG-400 and PEG-200 according to the relation between the polymerization degree and the property of PEG. Still further, the alcohol polymer permeation enhancer is preferably PEG-400.
In a specific example, the components of the skin tissue opacifying agent further preferably comprise heavy water, sucrose and PEG-400, i.e. the skin tissue opacifying agent comprises the following components in parts by mass:
100 parts of heavy water,
160-210 parts of sucrose
19-32 parts of PEG-400.
The invention also provides a preparation method of the skin tissue light transparent reagent in any example, which comprises the following steps:
mixing heavy water, saccharides and alcohol polymer penetration enhancer.
In a specific example, the method of preparing the skin tissue light transparent agent may be further optimized to include at least two steps:
step one: sugar is dissolved in heavy water to prepare a sugar-containing solution.
Further, the sugar-containing solution was prepared by mixing a saccharide with heavy water in a mass/volume ratio of (1.6-2.1) g/1 mL. The sugar-containing solution is prepared according to the proportion range, and the further prepared skin tissue light transparent reagent is more beneficial to the dehydration of skin tissue and is further more beneficial to the transparent exposure of skin tissue to cortical blood vessels. It will be appreciated that the mass to volume ratio of saccharide to heavy water can be, for example, but not limited to, 1.6g:1, 1.65g:1mL, 1.68g:1mL, 1.7g:1mL, 1.75g:1mL, 1.78g:1mL, 1.8g:1mL, 1.84g:1mL, 1.87g:1mL, 1.9g:1mL, 1.95g:1mL, 2g:1mL, 2.03g:1mL, 2.1g:1mL, and the like. Further, the sugar-containing solution was prepared by mixing a saccharide with heavy water in a mass/volume ratio of (1.85-2.05) g/1 mL. Further, the sugar-containing solution was prepared by mixing sugar and heavy water in a mass-to-volume ratio of 2.03 g/1 mL.
Step two: the sugar-containing solution is mixed with an alcohol polymer permeation enhancer.
Further, the skin tissue light transparent reagent is prepared by mixing a sugar-containing solution and an alcohol polymer permeation enhancer according to the volume ratio of (3.5-5.5): 1. Mixing at this volume ratio ensures that the prepared skin tissue light transparent agent has an optimal transparent effect, and that too high a volume ratio or too low a volume ratio reduces the transparent effect of the skin tissue. Further, the volume ratio of sugar-containing solution to alcohol polymer permeation enhancer may be, for example, but not limited to, 3.5:1, 3.6:1, 3.7:1, 3.8:1, 3.9:1, 4:1, 4.1:1, 4.2:1, 4.3:1, 4.4:1, 4.5:1, 4.6:1, 4.7:1, 4.8:1, 4.9:1, 5:1, 5.1:1, 5.2:1, 5.3:1, 5.4:1, 5.5:1. Further, the volume ratio of the sugar-containing solution to the alcohol polymer permeation enhancer is (4-5): 1. Further, the volume ratio of the sugar-containing solution to the alcohol polymer permeation enhancer is 4:1.
In a specific example, the skin tissue light transparent agent comprises heavy water, sucrose and PEG-400 as raw materials, and the preparation method comprises the steps of firstly preparing sucrose and heavy water into a sugar-containing solution according to a mass volume ratio of 2.03:1, and then mixing the sugar-containing solution and PEG-400 according to a volume ratio of 4:1. By adopting the specific component type and combining the specific composition proportion, the inventor discovers that the skin tissue light transparent reagent prepared by the method has the most obvious effect on promoting the skin tissue light transparency and high-resolution imaging.
The invention also provides the application of the skin tissue light transparent reagent in any embodiment in preparation of an optical imaging auxiliary preparation.
It can be appreciated that the optical imaging auxiliary preparation prepared by using the skin tissue light transparent reagent has better transparent capability on the skin of all parts. After the preparation is acted on the surface of the skin of the head of the living animal, the skin becomes transparent to light, thereby realizing the visualization of cortical blood vessels. Further, the information such as the cortical vascular structure, the blood flow distribution and the like can be known by combining an imaging technology.
It will be appreciated that the above-described optical imaging aids may be used in non-invasive applications for non-diagnostic and therapeutic purposes, such as non-invasive cerebral blood flow detection, non-invasive cerebral blood oxygen assessment, cortical neuron detection, etc., for living animals such as mice.
In one specific example, an optical imaging aid may be used to perform non-destructive optical imaging of the cerebral cortex.
Further, the optical imaging in a lossless manner comprises the steps of:
the skin tissue photopermeability agent is applied to the scalp surface to transparence the scalp and expose the cortical blood vessels, and then imaging is performed.
Further, the amount of the optical imaging assistant preparation applied to the scalp surface was 0.2mL/cm 2 ～1mL/cm 2 。
It will be appreciated that the amount of the optical imaging aid applied to the scalp surface may be, for example, but not limited to, 0.5mL/cm 2 、0.6mL/cm 2 、0.7mL/cm 2 、0.8mL/cm 2 、0.9mL/cm 2 、1mL/cm 2 Etc.
Further, the time for transparentizing the scalp after the optical imaging assistant preparation is coated on the scalp surface is 5min to 10min.
It is to be understood that the imaging method employed may be, for example, but not limited to, any one of OCT imaging, two-photon fluorescence imaging, near infrared imaging, and photoacoustic imaging.
OCT imaging is optical coherence tomography imaging, utilizes the low coherence principle of light to acquire depth information of tissues, is an interference imaging technology, and has the advantages of low loss, high resolution, non-invasiveness and the like. The two-photon fluorescence imaging uses the principle of two-photon absorption to excite and form fluorescence, and has strong penetrability and higher imaging depth. Near infrared imaging comprises near infrared high (multi) spectrum imaging and near infrared microscopic spectrum imaging, is suitable for in-situ determination of tissues, and is rapid and lossless. The photoacoustic imaging adopts light excitation to generate a photoacoustic signal, and can reconstruct a light absorption distribution image in tissues according to the detected photoacoustic signal, so that the photoacoustic imaging method has the advantages of high selectivity, deep penetrability, high resolution and the like. OCT imaging, two-photon fluorescence imaging, near infrared imaging and photoacoustic imaging are all noninvasive nondestructive biomedical imaging methods, and compared with the traditional method for establishing a cranium window by using the initial skin, the skin tissue light transparent reagent provided by the invention can realize high-resolution imaging of cortical blood vessels and cells under the condition of keeping the skin and the skull intact by combining the noninvasive nondestructive biomedical imaging methods.
It can be appreciated that the imaging data obtained by performing the nondestructive optical imaging on the cerebral cortex by using the optical imaging auxiliary preparation cannot be directly used as a disease diagnosis result, and other indexes such as blood flow rate, blood oxygen saturation and the like need to be combined for comprehensive judgment.
The skin tissue light transparent reagent provided by the invention is prepared from raw materials comprising heavy water, saccharides and alcohol polymer permeation promoters in a specific proportion, can be used for realizing skin tissue transparency by coating the skin tissue light transparent reagent on the surface of a cortex, is further applied to preparation of an optical imaging auxiliary preparation, is used for non-invasive cortex optical imaging, has high transparency speed and good imaging effect, is a nondestructive optical imaging method, is simple in operation method, is suitable for various imaging technologies such as OCT imaging, two-photon fluorescence imaging, near infrared imaging and photoacoustic imaging, and has a wide application range.
The following are specific examples. In the following specific examples, all components may be commercially available unless otherwise specified.
Preparation of first portion skin tissue light-transparentizing agent
Example 1
1. The formula comprises the following components: heavy water, sucrose, PEG-400.
2. The preparation method comprises the following steps:
(1) Sucrose and heavy water were prepared in a mass to volume ratio of 2.03g to 1mL to form a sucrose solution.
(2) Mixing sucrose solution with PEG-400 at a volume ratio of 4:1.
Comparative example 1
1. The formula comprises the following components: heavy water, sucrose
2. The preparation method comprises the following steps:
(1) Sucrose and heavy water were prepared in a mass to volume ratio of 2.03g to 1mL to form a sucrose solution.
Comparative example 2
1. The formula comprises the following components: heavy water and fructose
2. The preparation method comprises the following steps:
(1) Fructose and heavy water were prepared in a mass to volume ratio of 2.03g:1mL to give a fructose solution.
Comparative example 3
1. The formula comprises the following components: heavy water, sucrose, PEG-400.
2. The preparation method comprises the following steps:
(1) Sucrose and heavy water were prepared in a mass to volume ratio of 2.03g to 1mL to form a sucrose solution.
(2) Mixing sucrose solution with PEG-400 at a volume ratio of 3:1.
As shown in fig. 2, the skin tissue light transparent agent prepared in example 1 and comparative examples 1 to 2 was subjected to a transparency capability performance test, and the specific test method is as follows: several fresh mouse scalp samples were soaked in the skin tissue light transparent reagents prepared in example 1 and comparative examples 1 to 2 for 10 minutes, respectively, and the test results show that:
normal skin without treatment with the skin tissue photopermeable agent is extremely turbid and no resolution plate information can be observed; the skin tissue light transparent reagent prepared by adopting the fructose solution has a weak light transparent effect on skin tissue, but the resolution plate image is not very clear; the skin tissue light transparent reagent prepared by adopting the sucrose solution has a certain degree of enhancement on the light transparent effect of skin tissue compared with the fructose solution, but is still slightly blurred; after the skin tissue light transparent reagent prepared by mixing the sucrose solution and the PEG-400 is used for treating the skin tissue, the information of the resolution plate can be clearly observed, and the skin tissue light transparent effect is further improved.
As shown in fig. 3, the skin tissue light transparent agent prepared in example 1 and comparative example 3 was subjected to a transparent effect performance test, and the specific test method is as follows: several fresh mouse scalp samples were soaked in the skin tissue light transparent reagents prepared in example 1 and comparative example 3 for 10 minutes, respectively, and from the test results, it can be seen that:
the sucrose solution and PEG-400 are mixed according to the volume ratio of 4:1, and after the prepared skin tissue light transparent reagent is used for treating skin tissue, the information of the resolution plate can be clearly observed; and the volume ratio of sucrose solution to PEG-400 is 3:1, after the prepared skin tissue light transparent reagent is used for treating skin tissue, the information of the resolution plate can be observed, but the information is not clear and slightly blurred. It can be seen that too high a concentration of PEG-400 affects the transparency of the agent to skin tissue.
From the results of the performance tests of example 1 and comparative examples 1 to 3, it was revealed that the skin tissue light transparent agent of example 1 had a good light transparent effect after the skin tissue was treated, and thus the imaging ability was further investigated later using the protocol of example 1.
Imaging capability analysis of the second fraction as an optical imaging aid in mouse living cortical imaging applications
Example 2
Step one: preparation of skin tissue light transparent reagent:
1. the formula comprises the following components: heavy water, sucrose, PEG-400.
2. The preparation method comprises the following steps:
(1) Sucrose and heavy water were prepared in a mass to volume ratio of 2.03g to 1mL to form a sucrose solution.
(2) Mixing sucrose solution with PEG-400 at a volume ratio of 4:1.
Step two: imaging capability analysis:
anesthetizing mice, removing head hair, repeatedly lightly sticking head skin with medical adhesive tape to remove cutin, and then sticking an elliptical metal ring with 502 glue (4 cm) 2 ～5cm 2 ) At this location. And (3) smearing the skin tissue light transparent reagent prepared in the step one in a metal ring (about 1 mL), waiting for 5-10 min, and imaging by using a 1300nm OCT device after the large cortical blood vessel is invisible to naked eyes.
Fig. 4 shows the whole cerebral blood vessel structure image obtained by OCT imaging before and after the application of the skin tissue light transparent agent, it can be seen that only a few blood vessels are visible by OCT imaging before the application of the skin tissue light transparent agent, and the whole cerebral cortex blood vessels are clearly discernable after the light transparent effect is performed on the scalp surface layer by the skin tissue light transparent agent.
Example 3
Step one: preparation of skin tissue light transparent reagent:
1. the formula comprises the following components: heavy water, sucrose, PEG-400.
2. The preparation method comprises the following steps:
(1) Sucrose and heavy water were prepared in a mass to volume ratio of 2.03g to 1mL to form a sucrose solution.
(2) Mixing sucrose solution with PEG-400 at a volume ratio of 4:1.
Step two: imaging capability analysis:
anesthetizing mice, removing head hair, repeatedly lightly sticking head skin with medical adhesive tape to remove cutin, and then sticking an elliptical metal ring (1.5 cm) with 502 glue 2 ～2cm 2 ) At this location. And (3) smearing the skin tissue light transparent reagent prepared in the step one in a metal ring (about 0.5 mL), waiting for 5-10 min, invisible to naked eyes, marking a blood vessel by using a small amount of rhodamine dye, and then imaging by using a two-photon imaging system.
Fig. 5 shows the results of two-photon imaging before and after application of the skin tissue light transparent agent. Therefore, only autofluorescence signals of skin and skull tissues can be detected before the skin tissue light transparent reagent is adopted to carry out light transparent treatment on the scalp surface layer, after the light transparent effect, the cortical blood vessels and microglial cells are clearly visible, and the imaging depth is also obviously improved.
The technical features of the above embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The foregoing examples illustrate only a few embodiments of the invention, which are described in detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (5)
1. A skin tissue light transparent reagent, which is characterized by being prepared by the following steps:
preparing sucrose solution by sucrose and heavy water according to a mass volume ratio of 2.03g to 1mL;
and mixing the sucrose solution with PEG-400 according to the volume ratio of 4:1.
2. A method of preparing a skin tissue light transparent agent according to claim 1, comprising the steps of:
preparing sucrose solution by sucrose and heavy water according to a mass volume ratio of 2.03g to 1mL;
and mixing the sucrose solution with PEG-400 according to the volume ratio of 4:1.
3. Use of the skin tissue light transparent agent of claim 1 for the preparation of an optical imaging aid.
4. Use of an optically transparent agent for skin tissue according to claim 3 for the preparation of an optical imaging aid, wherein the optical imaging aid is used for the non-destructive optical imaging of the cerebral cortex.
5. Use of an optically transparent agent for skin tissue according to claim 4 for the preparation of an optical imaging aid, wherein the optical imaging in a non-destructive manner comprises the steps of:
the optical imaging assistant preparation is smeared on the surface of the scalp to make the scalp transparent and expose the cortical blood vessels, and then imaging is carried out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210444740.9A CN115554421B (en) | 2022-04-26 | 2022-04-26 | Skin tissue light transparent reagent and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210444740.9A CN115554421B (en) | 2022-04-26 | 2022-04-26 | Skin tissue light transparent reagent and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115554421A CN115554421A (en) | 2023-01-03 |
| CN115554421B true CN115554421B (en) | 2023-07-14 |
Family
ID=84737182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210444740.9A Active CN115554421B (en) | 2022-04-26 | 2022-04-26 | Skin tissue light transparent reagent and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115554421B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263678B (en) * | 2013-02-20 | 2015-05-20 | 华中科技大学 | Footpad skin tissue optical clearing agent |
| CN106390138A (en) * | 2016-08-29 | 2017-02-15 | 华中科技大学 | Skin tissue optical clearing solution, and preparation method and applications thereof |
| CN110694078A (en) * | 2019-10-22 | 2020-01-17 | 华中科技大学 | Skull light transparent reagent suitable for visible-near infrared two regions |
-
2022
- 2022-04-26 CN CN202210444740.9A patent/CN115554421B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115554421A (en) | 2023-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Genina et al. | Tissue optical immersion clearing | |
| Oliveira et al. | The optical clearing method: A new tool for Clinical Practice and Biomedical Engineering | |
| Genina et al. | Optical clearing of biological tissues: prospects of application in medical diagnostics and phototherapy | |
| Upputuri et al. | Recent advances in photoacoustic contrast agents for in vivo imaging | |
| EP1045717B1 (en) | Enhancing optical transparency of biological tissue | |
| DE60035174T2 (en) | INVASIVE METHOD FOR IN VIVO ANALYTIC MEASUREMENT | |
| JP3423892B2 (en) | Evaluation kit for skin properties | |
| Venugopal et al. | Clinical evaluation of a novel interstitial fluid sensor system for remote continuous alcohol monitoring | |
| EP2129283A1 (en) | Method for determining microvascular lesions | |
| Zhi et al. | Improve optical clearing of skin in vitro with propylene glycol as a penetration enhancer | |
| Lin et al. | Kinetics of optical clearing of human skin studied in vivo using portable Raman spectroscopy | |
| CN107033886A (en) | With being catalyzed and indicate difunctional fluorescent carbon point and its preparation method and application | |
| WO2019126735A1 (en) | Methods and systems for improved collection of interstitial fluid | |
| CN115554421B (en) | Skin tissue light transparent reagent and preparation method and application thereof | |
| Alaa | Recent Advances in the Laser Radiation Transport through the Head Tissues of Humans and Animals-A Review | |
| Genina et al. | Light–tissue interaction at optical clearing | |
| Perekatova et al. | Quantitative techniques for extraction of blood oxygenation from multispectral optoacoustic measurements | |
| Xia et al. | In vivo skin optical clearing for improving imaging and light-induced therapy: a review | |
| CN102284066B (en) | Application of whiteruss as optical transparency reinforcing agent | |
| CA3087289A1 (en) | Method and system for fluence matching in photoacoustic imaging | |
| Feng et al. | An optical clearing imaging window: Realization of mouse brain imaging and manipulation through scalp and skull | |
| CN105561347A (en) | Angiography enhancer | |
| Tuchin | Tissue optical clearing: New prospects in optical imaging and therapy | |
| CN116675877A (en) | Preparation method and application of double-network photonic crystal hydrogel for visual blood glucose detection | |
| JP3938745B2 (en) | Evaluation method of skin properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |